Literature DB >> 2566527

Screening for toxoplasmosis in pregnancy.

A A al-Meshari1, M N Chowdhury, S K Chattopadhyay, S K De Silva.   

Abstract

Randomly collected sera from 386 pregnant women attending obstetric and gynecology clinics at Kind Khalid University Hospital, Riyadh, Saudi Arabia, were examined for toxoplasma antibodies by five serological methods, i.e. latex agglutination test (LAT), two indirect hemagglutination tests (IHAT) (Carter-Wallace, USA and Ismunit, Italy), enzyme immunoassay (EIA) and indirect fluorescent antibody test (IFAT). The percentage of sensitivity, specificity and coincidence value of these tests were compared with IFAT which was used as a reference test. For routine screening of toxoplasmosis, LAT has proved in this study to be the most suitable test. The LAT is cost effective and easy to perform. In this study of the three tests (IFAT, EIA, immunosorbent agglutination assay) to demonstrate specific IgM for toxoplasmosis, the EIA test proved to be the most satisfactory because of its 99% specificity. If EIA equipment is available, it can be used for routine screening (IgG) as well as IgM determination. The incidence of toxoplasmosis in pregnant women varied between 25.4% and 36.3% depending on the method used.

Entities:  

Mesh:

Year:  1989        PMID: 2566527     DOI: 10.1016/0020-7292(89)90127-6

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  3 in total

1.  Sero-epidemiology and risk factors for Toxoplasma gondii among pregnant women in Arab and African countries.

Authors:  Mohamed Alkhatim Alsammani
Journal:  J Parasit Dis       Date:  2014-09-20

2.  A cost-benefit analysis of prenatal screening for toxoplasmosis.

Authors:  V S Sahai; H Onyett
Journal:  Can J Infect Dis       Date:  1996-07

3.  Sero-prevalence of toxoplasmosis in pregnant mothers and new born infants in eastern province, saudi arabia.

Authors:  A A Al-Mulhim; A M Al-Qurashi
Journal:  J Family Community Med       Date:  2001-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.